GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (LTS:0L49) » Definitions » Additional Paid-In Capital

SCYNEXIS (LTS:0L49) Additional Paid-In Capital : $428.9 Mil(As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is SCYNEXIS Additional Paid-In Capital?


SCYNEXIS's quarterly additional paid-in capital increased from Sep. 2023 ($427.6 Mil) to Dec. 2023 ($428.2 Mil) and increased from Dec. 2023 ($428.2 Mil) to Mar. 2024 ($428.9 Mil).

SCYNEXIS's annual additional paid-in capital increased from Dec. 2021 ($400.7 Mil) to Dec. 2022 ($425.5 Mil) and increased from Dec. 2022 ($425.5 Mil) to Dec. 2023 ($428.2 Mil).

SCYNEXIS Additional Paid-In Capital Historical Data

The historical data trend for SCYNEXIS's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS Additional Paid-In Capital Chart

SCYNEXIS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 284.31 349.35 400.71 425.49 428.17

SCYNEXIS Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 426.21 426.94 427.61 428.17 428.90

SCYNEXIS Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

SCYNEXIS Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

SCYNEXIS (LTS:0L49) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (LTS:0L49) » Definitions » Additional Paid-In Capital
Comparable Companies
BGXX DRRX SSIC DERM TKNO RMTI INCR SHWZ ESPR SCTL ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
SCYX:USA 135A:Germany
Address
1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
Website
https://www.scynexis.com
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

SCYNEXIS (LTS:0L49) Headlines

No Headlines